The Two Faces of Potent Antitumor Duocarmycin-Based Drugs: A Structural Dissection Reveals Disparate Motifs for DNA versus Aldehyde Dehydrogenase 1 Affinity
作者:Tanja Wirth、Galina F. Pestel、Vanessa Ganal、Thomas Kirmeier、Ingrid Schuberth、Theo Rein、Professor Lutz F. Tietze、Professor Stephan A. Sieber
DOI:10.1002/anie.201208941
日期:2013.7.1
Duocarmycin‐derived seco‐cyclopropabenzindole (CBI) drugs have been shown to bind DNA and an aldehyde dehydrogenase (ALDH1A1) in lung cancer cells. The removal of the DNA‐binding indole moiety results in a CBI compound that does not bind to DNA in whole cells but still exhibits remarkable cytotoxicity. This CBI compound has an increased affinity for ALDH1A1. Rh=rhodamine.
研究表明,杜卡霉素衍生的二十二烷基环丙苯并吲哚(CBI)药物可与肺癌细胞中的DNA和醛脱氢酶(ALDH1A1)结合。去除结合DNA的吲哚部分会导致CBI化合物不与整个细胞中的DNA结合,但仍表现出显着的细胞毒性。此CBI化合物对ALDH1A1的亲和力增加。Rh =若丹明。